EMA to Investigate Zydelig Following Adverse Events

The European Medicines Agency has launched an investigation into Gilead Sciences’ cancer drug Zydelig following an increase in serious adverse events.

The review of Zydelig — which is approved in the EU for the treatment of chronic lymphocytic leukemia and follicular lymphoma — was requested by the European Commission. Adverse events were observed in three clinical trials evaluating the drug in combination with other cancer medicines. The EMA declined to comment on the number of adverse events and deaths.